Literature DB >> 26799351

Management of Sleep Disorders in Children With Neurodevelopmental Disorders: A Review.

Allison Beck Blackmer1,2, James A Feinstein3,4.   

Abstract

Neurodevelopmental disorders (NDDs) are defined as a group of disorders caused by changes in early brain development, resulting in behavioral and cognitive alterations in sensory and motor systems, speech, and language. NDDs affect approximately 1-2% of the general population. Up to 80% of children with NDDs are reported to have disrupted sleep; subsequent deleterious effects on daytime behaviors, cognition, growth, and overall development of the child are commonly reported. Examples of NDDs discussed in this review include autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, and Smith-Magenis syndrome. The etiology of sleep disorders in children with NDDs is largely heterogeneous and disease specific. The diagnosis and management of sleep disorders in this population are complex, and little high-quality data exist to guide a consistent approach to therapy. Managing sleep disorders in children with NDDs is critical both for the child and for the family but is often frustrating due to the refractory nature of the problem. Sleep hygiene must be implemented as first-line therapy; if sleep hygiene alone fails, it should be combined with pharmacologic management. The available evidence for the use of common pharmacologic interventions, such as iron supplementation and melatonin, as well as less common interventions, such as melatonin receptor agonists, clonidine, gabapentin, hypnotics, trazodone, and atypical antipsychotics is reviewed. Further, parents and caregivers should be provided with appropriate education on the nature of the sleep disorders and the expectation for modest pharmacologic benefit, at best. Additional data from well-designed trials in children with NDDs are desperately needed to gain a better understanding of sleep pharmacotherapy including efficacy and safety implications. Until then, clinicians must rely on the limited available data, as well as clinical expertise, when managing sleep disorders in the population of children with NDDs.
© 2016 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  children; insomnia; neurodevelopmental disorders; pediatrics; pharmacotherapy; sleep disorders

Mesh:

Substances:

Year:  2016        PMID: 26799351     DOI: 10.1002/phar.1686

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  35 in total

Review 1.  Postintensive Care Syndrome in Pediatric Critical Care Survivors: Therapeutic Options to Improve Outcomes After Acquired Brain Injury.

Authors:  Cydni N Williams; Mary E Hartman; Kristin P Guilliams; Rejean M Guerriero; Juan A Piantino; Christopher C Bosworth; Skyler S Leonard; Kathryn Bradbury; Amanda Wagner; Trevor A Hall
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.598

2.  Mirtazapine for sleep disturbances in Angelman syndrome: a retrospective chart review of 8 pediatric cases.

Authors:  Emily Hanzlik; Sarah A Klinger; Robert Carson; Jessica Duis
Journal:  J Clin Sleep Med       Date:  2020-04-15       Impact factor: 4.062

3.  A Review of Sleep Disturbances among Infants and Children with Neurodevelopmental Disorders.

Authors:  Dana Kamara; Theodore P Beauchaine
Journal:  Rev J Autism Dev Disord       Date:  2019-12-26

Review 4.  Management of Self-injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview.

Authors:  Ashley Sabus; James Feinstein; Patrick Romani; Edward Goldson; Allison Blackmer
Journal:  Pharmacotherapy       Date:  2019-03-27       Impact factor: 4.705

5.  A Randomized, Crossover Trial of a Novel Sound-to-Sleep Mattress Technology in Children with Autism and Sleep Difficulties.

Authors:  Thomas W Frazier; Jyoti Krishna; Eric Klingemier; Mary Beukemann; Rawan Nawabit; Sally Ibrahim
Journal:  J Clin Sleep Med       Date:  2017-01-15       Impact factor: 4.062

6.  Chronic Medication Use in Children Insured by Medicaid: A Multistate Retrospective Cohort Study.

Authors:  James A Feinstein; Matt Hall; James W Antoon; Joanna Thomson; Juan Carlos Flores; Denise M Goodman; Eyal Cohen; Romuladus Azuine; Rishi Agrawal; Amy J Houtrow; Danielle D DeCourcey; Dennis Z Kuo; Ryan Coller; Dipika S Gaur; Jay G Berry
Journal:  Pediatrics       Date:  2019-04       Impact factor: 7.124

Review 7.  Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.

Authors:  Shweta Anand; Henry Tong; Frank M C Besag; Esther W Chan; Samuele Cortese; Ian C K Wong
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

8.  Composite Sleep Problems Observed Across Smith-Magenis Syndrome, MBD5-Associated Neurodevelopmental Disorder, Pitt-Hopkins Syndrome, and ASD.

Authors:  Anusha Gandhi; Dihong Zhou; Joseph Alaimo; Edwin Chon; Michael D Fountain; Sarah H Elsea
Journal:  J Autism Dev Disord       Date:  2021-06

9.  The Assessment and Treatment of Sleep Abnormalities in Children and Adolescents with Autism Spectrum Disorder: A Review.

Authors:  Mandeep Rana; Sanjeev Kothare; William DeBassio
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2021-02-01

10.  Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial.

Authors:  Masaharu Hayashi; Kazuo Mishima; Michio Fukumizu; Hiroyuki Takahashi; Yuko Ishikawa; Izumi Hamada; Hideyuki Sugioka; Osamu Yotsuya; Yushiro Yamashita
Journal:  J Autism Dev Disord       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.